Human Influenza: Clinical Trials

8 completed. 8 Phase 2, 1 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	8	Completed 8
Phase 3	1	Completed 1

Follow Human Influenza: new trials by email Literature Review of Human Influenza trials Research Report on Human Influenza

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Evaluate Safety and Immunogenicity of Trivalent Influenza Vaccine, Formulation 2015 Southern Hemisphere, When Administered to Healthy Adult Subjects. Aggripal® - Human Influenza	Phase 2	Completed	Novartis	126	2015-04-01	2015-10-19
Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above TIV - Human Influenza	Phase 2	Completed	Novartis Vaccines	126	2013-07-01	2014-03-12
Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age aTIV - Human Influenza	Phase 2	Completed	Novartis Vaccines	63	2013-07-01	2014-03-26
Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above Trivalent influenza virus vaccine (TIV) - Human Influenza	Phase 2	Completed	Novartis Vaccines	126	2012-07-01	2015-11-30
Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects Adjuvanted Trivalent Influenza Virus Vaccine (aTIV) - Human Influenza	Phase 2	Completed	Novartis Vaccines	63	2012-07-01	2014-04-21
Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects MF59C.1-adjuvanted subunit influenza vaccine, Sub unit, Inactivated, Influenza vaccine - Seasonal Influenza, Influenza	Phase 2	Completed	Novartis Vaccines	84	2011-05-01	2021-04-19
Bangladesh Secondary Transmission Handwashing Protocol Soap - Human Influenza	Phase 2	Completed	International Centre for Diarrhoeal Disease Research, Bangladesh	6600	2009-06-01	2010-12-30
Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza. Enisamium Iodide, Placebo - Acute Respiratory Viral Infections, Human Influenza	Phase 2 / Phase 3	Completed	Joint Stock Company "Farmak"	100	2009-04-13	2026-01-08

Narrower conditions

Influenza, Human (8)  ·  Virus Diseases (1)

Broader conditions

Infections (8)  ·  Orthomyxoviridae Infections (8)  ·  RNA Virus Infections (8)  ·  Respiratory Tract Diseases (8)  ·  Respiratory Tract Infections (8)  ·  Virus Diseases (7)

Interventions

Influenza Vaccines (1)  ·  Soaps (1)  ·  enisamium iodide (1)

Sponsors

Novartis Vaccines (5)  ·  International Centre for Diarrhoeal Disease Research, Bangladesh (1)  ·  Joint Stock Company "Farmak" (1)  ·  Novartis (1)

Countries

Belgium (5)  ·  Bangladesh (1)  ·  Brazil (1)

Top investigators

Eduardo Azziz-Baumgartner, MD, MPH (1)  ·  Ekatarina A. Okhapkina (1)

Results publications

PMID 25037034, PMID 26066651, PMID 33215698, PMID 33558285, PMID 36715243